Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Balthasar

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|July 26, 2023
Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug ConjugatesToan D Nguyen, Brandon M Bordeau, Joseph P Balthasar
Cancers|February 11, 2023
Mechanisms of ADC Toxicity and Strategies to Increase ADC TolerabilityToan D Nguyen, Brandon M Bordeau, Joseph P Balthasar
Journal of Pharmaceutical Sciences|September 25, 2004
Antibody pharmacokinetics and pharmacodynamicsEvelyn D Lobo, Ryan J Hansen, Joseph P Balthasar
Journal of Immunoassay & Immunochemistry|April 15, 2010
An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasmaShweta R Urva, Victor C Yang, Joseph P Balthasar
Journal of Immunoassay & Immunochemistry|September 10, 2009
Development and validation of an enzyme linked immunosorbent assay for the quantification of carcinoembryonic antigen in mouse plasmaShweta R Urva, Victor C Yang, Joseph P Balthasar
Journal of Pharmaceutical Sciences|September 24, 2009
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibodyShweta R Urva, Victor C Yang, Joseph P Balthasar
Journal of Pharmaceutical Sciences|July 29, 2003
Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in miceEvelyn D Lobo, David M Soda, Joseph P Balthasar
Pharmaceutical Research|February 27, 2004
Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocolEllen Q Wang, Joseph P Balthasar, Ho-Leung Fung
Journal of Pharmaceutical Sciences|October 16, 2018
Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse ModelsJoseph Ryan Polli, Frank A Engler, Joseph P Balthasar
Journal of Biomedical Materials Research. Part A|August 19, 2005
A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studiesEmel Emregul, Allan David, Joseph P Balthasar, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|July 26, 2023
Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug ConjugatesToan D Nguyen, Brandon M Bordeau, Joseph P Balthasar
Cancers|February 11, 2023
Mechanisms of ADC Toxicity and Strategies to Increase ADC TolerabilityToan D Nguyen, Brandon M Bordeau, Joseph P Balthasar
Journal of Pharmaceutical Sciences|September 25, 2004
Antibody pharmacokinetics and pharmacodynamicsEvelyn D Lobo, Ryan J Hansen, Joseph P Balthasar
Journal of Immunoassay & Immunochemistry|April 15, 2010
An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasmaShweta R Urva, Victor C Yang, Joseph P Balthasar
Journal of Immunoassay & Immunochemistry|September 10, 2009
Development and validation of an enzyme linked immunosorbent assay for the quantification of carcinoembryonic antigen in mouse plasmaShweta R Urva, Victor C Yang, Joseph P Balthasar
Journal of Pharmaceutical Sciences|September 24, 2009
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibodyShweta R Urva, Victor C Yang, Joseph P Balthasar
Journal of Pharmaceutical Sciences|July 29, 2003
Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in miceEvelyn D Lobo, David M Soda, Joseph P Balthasar
Pharmaceutical Research|February 27, 2004
Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocolEllen Q Wang, Joseph P Balthasar, Ho-Leung Fung
Journal of Pharmaceutical Sciences|October 16, 2018
Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse ModelsJoseph Ryan Polli, Frank A Engler, Joseph P Balthasar
Journal of Biomedical Materials Research. Part A|August 19, 2005
A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studiesEmel Emregul, Allan David, Joseph P Balthasar, et al.
Pageof 9